Literature DB >> 16051322

The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.

E Kastritis1, A Bamias, E Efstathiou, D Gika, G Bozas, P Zorzou, K Sarris, C Papadimitriou, M A Dimopoulos.   

Abstract

BACKGROUND: Data about the outcome and prognostic factors in the group of patients with non-squamous cell advanced or recurrent carcinomas of the uterine cervix are limited. We compared the outcome of patients with non-squamous with that of squamous cell carcinomas after platinum-based combination chemotherapy as first line therapy for stage IV or recurrent cervical carcinoma. PATIENTS AND METHODS: A total of 200 patients with stage IV or recurrent carcinomas of the cervix received platinum-based combination chemotherapy and were included in our analysis.
RESULTS: There were 58 patients with non-squamous and 142 patients with squamous cell carcinomas. Response to chemotherapy was 53.5% in non-squamous vs. 43.5% in squamous carcinomas. Histology was not an independent predictor of tumor response (P = 0.797). Response rates were lower in patients with relapse only in a previously irradiated area in both squamous (26.9% vs. 53.5%, P = 0.005) and non-squamous carcinomas (47.1% vs. 65%, P = 0.270). Weight loss was the only significant predictor of survival in non-squamous histology patients (P < 0.0001). There was no significant difference in median survival between squamous (11.57 months [95% CI 9.35-13.79]) and non-squamous carcinomas (19.05 months [95% CI 13.63-24.47]) (P = 0.064). After adjustment for independent prognostic factors (ECOG performance status and weight loss), differences in survival remained not significant.
CONCLUSION: Our study showed a similar outcome for both squamous and non-squamous stage IV or recurrent cervical carcinomas treated with platinum-based combination chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051322     DOI: 10.1016/j.ygyno.2005.06.024

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  A rare case of minimal deviation adenocarcinoma of the uterine cervix in a renal transplant recipient.

Authors:  D M Fanning; C Gulmann; D P Hickey; D M Little
Journal:  Ir J Med Sci       Date:  2009-02-03       Impact factor: 1.568

2.  Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy.

Authors:  Jian Z Wang; Nina A Mayr; Dongqing Zhang; Kaile Li; John C Grecula; Joseph F Montebello; Simon S Lo; William T C Yuh
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

3.  Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: cervical cancer as a model.

Authors:  Nina A Mayr; Zhibin Huang; Jian Z Wang; Simon S Lo; Joline M Fan; John C Grecula; Steffen Sammet; Christina L Sammet; Guang Jia; Jun Zhang; Michael V Knopp; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-28       Impact factor: 7.038

Review 4.  Adenocarcinoma of the uterine cervix: why is it different?

Authors:  Keiichi Fujiwara; Bradley Monk; Mojgan Devouassoux-Shisheboran
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

5.  Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.

Authors:  Nina A Mayr; William T C Yuh; David Jajoura; Jian Z Wang; Simon S Lo; Joseph F Montebello; Kyle Porter; Dongqing Zhang; D Scott McMeekin; John M Buatti
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

6.  Validation of optimal DCE-MRI perfusion threshold to classify at-risk tumor imaging voxels in heterogeneous cervical cancer for outcome prediction.

Authors:  Zhibin Huang; Kevin A Yuh; Simon S Lo; John C Grecula; Steffen Sammet; Christina L Sammet; Guang Jia; Michael V Knopp; Qiang Wu; Norman J Beauchamp; William T C Yuh; Roy Wang; Nina A Mayr
Journal:  Magn Reson Imaging       Date:  2014-08-29       Impact factor: 2.546

7.  Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer.

Authors:  Nina A Mayr; Jian Z Wang; Simon S Lo; Dongqing Zhang; John C Grecula; Lanchun Lu; Joseph F Montebello; Jeffrey M Fowler; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-23       Impact factor: 7.038

8.  Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Authors:  Mihae Song; Robert S DiPaola; Bernadette M Cracchiolo; Darlene G Gibbon; Mira Hellmann; Wilberto Nieves-Neira; Ami Vaidya; Allison R Wagreich; Weichung J Shih; Lorna Rodriguez-Rodriguez
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

9.  Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients.

Authors:  Suk Hee Heo; Sang Soo Shin; Jin Woong Kim; Hyo Soon Lim; Yong Yeon Jeong; Woo Dae Kang; Seok Mo Kim; Heoung Keun Kang
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

10.  Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.

Authors:  Koji Matsuo; Muneaki Shimada; Satoshi Yamaguchi; Junzo Kigawa; Hideki Tokunaga; Tsutomu Tabata; Junichi Kodama; Kei Kawana; Mikio Mikami; Toru Sugiyama
Journal:  J Clin Med       Date:  2019-01-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.